Nerve stimulation offers OAB patients sustained benefits at 2 years
The Urgent PC Neuromodulation System (Uroplasty, Inc., Minneapolis) demonstrated sustained safety and efficacy over 24 months in patients with overactive bladder, the authors of a recent study reported.
The Urgent PC Neuromodulation System (Uroplasty, Inc., Minneapolis) demonstrated sustained safety and efficacy over 24 months in patients with overactive bladder, the authors of a recent study reported.
The treatment was given at an average of 1.3 times per month and was part of the STEP (Sustained Therapeutic Effects of Percutaneous Tibial Nerve Stimulation) Study on percutaneous tibial nerve stimulation treatments for OAB.
The multicenter trial, led by Kenneth M. Peters, MD, of Beaumont Hospital in Royal Oak, MI, followed for up to 24 months patients who initially responded to 12 weekly Urgent PC treatments. There were no device-related adverse events throughout the study, results of which were published online in Neurourology and Urodynamics (June 5, 2012).
“This publication of long-term data demonstrates the durability of PTNS therapy and the continued success that patients experience after their initial 12 weekly treatments,” Dr. Peters said. “Unlike other treatments for the chronic condition of OAB that require continuous treatment to maintain their effects, this therapy can be administered at approximately monthly intervals to sustain voiding symptom improvement.
"It is office-based and minimally invasive, making it an ideal therapy option for those patients refractory to OAB drug therapy and other conservative therapy."
Dr. Peters is a consultant/adviser for Uroplasty.
Go back to this issue of Urology Times eNews.
Related Content
AUA releases guidelines on OAB, hematuria, vasectomy, urodynamics
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
